Telmisartan (Semintra) for Proteinuria and Hypertension in Cats with CKD

Bottom line

• Telmisartan proved noninferior to benazepril and significantly decreased urine protein-to-creatinine (UP/C) ratio at all assessment points in a 224-cat multicenter blinded clinical trial; benazepril did not achieve statistical significance vs baseline.
• FDA approved Semintra in May 2018 as the first drug approved for systemic hypertension in cats; EMA approval preceded this in 2013.
• Telmisartan is an angiotensin II receptor blocker (ARB) acting at AT1 receptors; ARB blockade in cats reduces both systemic blood pressure and glomerular efferent arteriolar tone, decreasing proteinuria.
• A European clinical trial demonstrated efficacy of long-term oral telmisartan for reducing systemic blood pressure in cats with hypertension.
• Both telmisartan and benazepril were well tolerated and safe in the Sent et al. comparison study.

Drug facts

• Class: Angiotensin II receptor blocker (ARB); AT1 receptor antagonist
• Mechanism: Selectively and competitively antagonizes AT1 (angiotensin II type 1) receptors, reducing angiotensin II-mediated vasoconstriction and aldosterone secretion; in the kidney, reduces glomerular efferent arteriolar pressure, lowering intraglomerular hypertension and proteinuria
• Route: Oral solution (1 mg/mL); Semintra
• Indication: FDA-approved for systemic hypertension in cats; EMA-approved for reduction of proteinuria associated with CKD in cats
• Approval: EMA 2013 (Boehringer Ingelheim); FDA May 2018 (first FDA approval for feline systemic hypertension)
• Label contraindications: Per label — not recommended during pregnancy or lactation; caution with concurrent ACE inhibitor use (risk of additive hypotension and renal effects)
• Label common AEs: Per label — hypotension; azotaemia; anorexia; vomiting

A specific patient on telmisartan?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=telmisartan-feline-ckd-proteinuria

What the evidence shows

Telmisartan vs benazepril in feline CKD: Sent et al., 2015

Sent et al. conducted a prospective, multicenter, controlled, randomized, parallel group, blinded clinical trial with a noninferiority design, enrolling 224 cats with CKD allocated 1:1 to telmisartan or benazepril administered orally once daily. The primary endpoint was change in proteinuria based on log-transformed weighted average of UP/C change from baseline. Telmisartan proved noninferior to benazepril and significantly decreased proteinuria relative to baseline at all assessment points, whereas benazepril did not achieve statistical significance relative to baseline. Both agents were well tolerated and safe across the study duration.

This study is the foundational comparative evidence for telmisartan in feline CKD proteinuria and underpins the EMA indication. The specific dose regimens employed should be confirmed against current prescribing information.

Systemic hypertension in cats: European clinical trial

A prospective European clinical trial evaluated long-term oral telmisartan for systemic hypertension in cats. Reduction in blood pressure was demonstrated to be significant and sustained over the treatment period. These data support telmisartan as a first-line option for feline systemic hypertension, the indication for which FDA approval was granted in 2018.

FDA approval and regulatory context

The AVMA reported in 2018 that FDA granted approval of Semintra as the first FDA-approved animal drug to control systemic hypertension in cats. The dual regulatory footprint — EMA for proteinuria in CKD cats, FDA for systemic hypertension in cats — reflects the breadth of the clinical evidence and the clinical burden of renal and cardiovascular disease in the feline population.

How this fits clinical practice

Telmisartan is now a central agent in the management of feline CKD-associated proteinuria and systemic hypertension. In cats with CKD and concurrent proteinuria, telmisartan offers a single agent that addresses both concerns. The comparison study with benazepril is clinically important: it suggests that ARB blockade may be more effective than ACE inhibition at consistently reducing UP/C in cats, though the underlying mechanism (full AT1 blockade vs upstream ACE inhibition) and potential differences in tolerability in individual patients should be considered.

Monitoring recommendations include baseline and periodic blood pressure, serum creatinine, BUN, electrolytes, and UP/C; consult IRIS guidelines and current formulary for monitoring intervals and dose titration guidance.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=telmisartan-feline-ckd-proteinuria

References

1. Sent U et al. Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4895689/
2. Glaus TM et al. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6430888/
3. AVMA. FDA approves new feline hypertension drug. JAVMA News. 2018-08-01. https://www.avma.org/javma-news/2018-08-01/fda-approves-new-feline-hypertension-drug

Changelog

• 2026-06-06: First published.

Related reads

• Mirtazapine Transdermal Cats Appetite
• Frunevetmab (Solensia) for Feline Osteoarthritis: Effectiveness and Real-World Safety